Award
National Heart, Lung, and Blood Institute 5K23HL159313-05
Antiangiogenic Therapy to Reduce Bleeding and Improve Health-Related Quality of Life in Hereditary Hemorrhagic Telangiectasia
Recipient
Massachusetts General Hospital
Award Amount
$199,800.00
Ceiling
$199,800.00
Awarded
June 23, 2026
Identifier
5K23HL159313-05
NIH-funded phase II clinical trial evaluating systemic bevacizumab to reduce bleeding and improve quality of life in patients with hereditary hemorrhagic telangiectasia, including biomarker analysis.
Description
This project aims to evaluate the efficacy of systemic bevacizumab in reducing chronic bleeding and anemia in hereditary hemorrhagic telangiectasia (HHT) through a phase II clinical trial. The primary endpoint is a composite Hematologic Support Score (HSS) measuring red cell transfusions and iron infusions. Secondary endpoints include quality of life improvements assessed via PROMIS instruments and a specific HHT QOL tool. The study will also analyze angiogenic biomarkers to understand bevacizumab's impact on the angiogenic milieu in HHT.